![]() |
Name |
Botryopyrone
|
Molecular Formula | C10H12O5 | |
IUPAC Name* |
3-(4-methoxy-6-oxopyran-2-yl)butanoicacid
|
|
SMILES |
COc1cc(C(C)CC(=O)O)oc(=O)c1
|
|
InChI |
InChI=1S/C10H12O5/c1-6(3-9(11)12)8-4-7(14-2)5-10(13)15-8/h4-6H,3H2,1-2H3,(H,11,12)/t6-/m1/s1
|
|
InChIKey |
GXBVESSBUINHIO-ZCFIWIBFSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 212.2 | ALogp: | 1.2 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 76.7 | Aromatic Rings: | 1 |
Heavy Atoms: | 15 | QED Weighted: | 0.821 |
Caco-2 Permeability: | -4.721 | MDCK Permeability: | 0.00008890 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.045 |
Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.014 |
30% Bioavailability (F30%): | 0.938 |
Blood-Brain-Barrier Penetration (BBB): | 0.134 | Plasma Protein Binding (PPB): | 77.41% |
Volume Distribution (VD): | 0.252 | Fu: | 22.73% |
CYP1A2-inhibitor: | 0.038 | CYP1A2-substrate: | 0.66 |
CYP2C19-inhibitor: | 0.028 | CYP2C19-substrate: | 0.067 |
CYP2C9-inhibitor: | 0.016 | CYP2C9-substrate: | 0.929 |
CYP2D6-inhibitor: | 0.02 | CYP2D6-substrate: | 0.426 |
CYP3A4-inhibitor: | 0.009 | CYP3A4-substrate: | 0.12 |
Clearance (CL): | 10.293 | Half-life (T1/2): | 0.838 |
hERG Blockers: | 0.007 | Human Hepatotoxicity (H-HT): | 0.66 |
Drug-inuced Liver Injury (DILI): | 0.815 | AMES Toxicity: | 0.011 |
Rat Oral Acute Toxicity: | 0.132 | Maximum Recommended Daily Dose: | 0.224 |
Skin Sensitization: | 0.193 | Carcinogencity: | 0.159 |
Eye Corrosion: | 0.708 | Eye Irritation: | 0.795 |
Respiratory Toxicity: | 0.077 |